Previous 10 | Next 10 |
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday,...
SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its fourth quarter and full-year 2018 financial results on Tuesday, February 26, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and liv...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor typ...
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cameco Corporation (NYSE:CCJ), American Equity Investment Life Holding...
Arena Pharmaceuticals (ARNA) investors have something to celebrate on Jan. 24. The $1.2 billion deal with United Therapeutics (UTHR) has cleared the HSR regulatory review and is now closed. With the closing, Arena received its non-refundable, up-front cash payment of $800 million. There are ...
United Therapeutics (NASDAQ: UTHR ) has closed its license agreement with Arena Pharmaceuticals (NASDAQ: ARNA ). More news on: United Therapeutics Corporation, Arena Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
MannKind ( MNKD ) investors are pretty keen on the television advertising campaign for Afrezza which was re-launched by the company in the middle of January. Many investors are excited because they are seeing an ad on television for the first time, or in some cases seeing the ad run with great...
SAN DIEGO , Jan. 24, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-ge...
RESEARCH TRIANGLE PARK, N.C. , Jan. 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...